A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer - ATLANTIC

Exclusion Criteria

• - Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
• - Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).
• - Active or prior autoimmune disease or history of immunodeficiency
• - Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
• - Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
• - Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy.
• - Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
• - Active or prior documented inflammatory bowel disease (eg, Crohn’s disease, ulcerative colitis)